Metabolite Profiling for Radiation Therapy Toxicity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiation therapy for cancer, such as prostate cancer, often results in adverse reactions due to variations in patients' normal tissue sensitivities, leading to toxicities and quality of life issues, despite advanced technologies like IMRT and proton beam therapy, as existing methods fail to predict individual patient responses effectively.
Innovation Solution
A method involving the analysis of a subject's metabolite profile to determine altered components compared to a normal profile, identifying specific biomarkers like geranyl pyrophosphate, glucose-1-phosphate, and 3-hydroxy-3-methylglutaryl-CoA, or lysophosphatidic acid, lysophosphatidylcholine, and ceramide levels, to predict the risk of adverse reactions, allowing for personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation therapy is administered to control cancer, then tumor control is improved, but normal tissue toxicity increases
Solution Approach 1:
The patent applies preliminary action by measuring metabolite levels in blood samples before radiation therapy to identify patients at high risk for toxicity. This allows clinicians to anticipate adverse reactions and adjust treatment plans beforehand, preventing or mitigating normal tissue damage while maintaining effective tumor control.
2Reliability
If high radiation doses are delivered to tumors, then tumor control is improved, but normal tissue toxicities increase
Solution Approach 1:
The patent applies local quality by using metabolite profiling to identify specific patient subgroups with heightened sensitivity to radiation. This enables personalized treatment approaches where radiation dosing can be optimized for each patient's metabolic characteristics, delivering effective tumor control while minimizing toxicity in susceptible individuals.
3Manufacturing precision
If advanced radiation technologies like IMRT and proton beam therapy are used, then conformal targeting is improved, but normal tissue toxicities persist
Solution Approach 1:
The patent applies feedback by using metabolite level measurements to inform and adjust radiation therapy decisions. The metabolic profile provides real-time information about patient susceptibility, allowing clinicians to modify treatment plans based on individual patient responses rather than relying solely on anatomical targeting precision.
4Measurement precision
If metabolite profiling is performed to predict toxicity risk, then patient stratification is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies self-service by utilizing metabolites that are naturally present in patient blood samples. The metabolic profile emerges from the patient's own biology without requiring external labeling or complex preparation, simplifying the diagnostic process while providing precise patient stratification for radiation therapy risk assessment.
Data Source
AI summary
Methods of treating with radiation therapy a subject having cancer, in which the method comprises administering radiation therapy to the subject. The subject does not have an increased risk of having an adverse reaction to radiation therapy. The subject has an increased risk of an adverse reaction to radiation therapy when the subject's level of each component in a component profile from a sample of the subject is altered as compared to the normal level of each component. The component profile may comprise a metabolite panel of geranyl pyrophosphate, glucose-1-phosphate, and 3-hydroxy-3-methylglutaryl-CoA; a lipid panel of LPA 18:0, LPA 16:0, LPC 20:2, CER 24:0, and LPI 16:1; or a combination of these panels. The component profile may also comprise a metabolite panel of metanephrine, tryptophan, xanthurenic acid, and pantothenate; a lipid panel of LPA 18:0, DAG 16:0/18:0, LPA 16:0, and DAG 18:1/18:1; or a combination of these panels.